Skip to main content

Requiring
IV Administration

Consider Rapivab® (peramivir injection) intravenous (IV) administration for these patients

Patients with influenza may require IV administration for hydration or delivery of medications, depending on their physical condition. In these situations, Rapivab IV administration may be a seamless option for both you and your patients.1

In the United States, dysphagia affects 300,000 to 600,000 persons yearly, and conservative estimates suggest it affects 15% of the elderly population.5

Patients with dysphagia or other conditions that can include difficulty swallowing, like dementia, may also have difficulty with oral suspensions.5

Swallowing difficulties may result from physical impairment or psychological aversion.6

  • Receiving IV fluids

    According to a 2016 study, 38% of patients who come to the emergency department (ED)
    with influenza-like illness require an IV for hydration or medication.2

  • Swallowing issues

    Rapivab may avoid potential gastrointestional absorption issues due to nausea, vomiting, or difficulty swallowing.3,4

  • Absorption challenges

    Rapivab mitigates absorption challenges by offering complete bioavailability if the entire
    infusion is received.

  • Nonfunctional gastrointestinal tract

    Rapivab, which is administered as an IV infusion, bypasses the gastrointestinal (GI)
    tract to deliver antiviral influenza therapy.7

References: 1. National Home Infusion Association. Infusion FAQs. National Home Infusion Association website. https://www.nhia.org/faqs.cfm Accessed April 19, 2017. 2. Cerebroglobal Healthcare Research & Analytics. US findings: Rapivab forecasting study final report. Data on file. 2016. 3. Hueston WJ, Casey BR. Respiratory problems. In: South-Paul JE, Matheny SC, Lewis EL, eds. CURRENT Diagnosis & Treatment in Family Medicine. 3rd ed. New York, NY: McGraw-Hill; 2011. http://accessmedicine.mhmedical.com/content.aspx?bookid=377&sectionid=40349419. Accessed January 28, 2017. 4. Dychter SS, Gold DA, Carson D, Haller W. Intravenous therapy: a review of complications and economic considerations of peripheral access. J Infus Nurs. 2012;35(2):84-91. 5. Sura L, Madhavan A, Carnaby G, Crary MA. Dysphagia in the elderly: management and nutritional considerations. Clin Interv Aging. 2012;7:287-298. 6. Wright D, Tomlin S. How to help if a patient can’t swallow. Pharm J. 2011;286:271-274. http://www.pharmaceutical-journal.com/files/rps-pjonline/pdf/PJ050311_271-274.pdf. Published March 5, 2011. Accessed December 12, 2016. 7. Rapivab [package insert]. Summit, NJ: Seqirus USA Inc; 2017.
Important Safety Information  

Important Safety Information

Rapivab® (peramivir injection) is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days.

Efficacy of Rapivab was based on clinical trials in which the predominant influenza virus type was influenza A; a limited number of subjects infected with influenza B virus were enrolled.

Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Rapivab.

Efficacy could not be established in patients with serious influenza requiring hospitalization.

Contraindications

Rapivab is contraindicated in patients with known serious hypersensitivity or anaphylaxis to peramivir or any component of the product. Severe allergic reactions have included anaphylaxis, erythema multiforme, and Stevens-Johnson syndrome.

Warnings and Precautions
  • Rare cases of serious skin reactions, including erythema multiforme, have been reported with Rapivab in clinical studies and in postmarketing experience. Cases of anaphylaxis and Stevens-Johnson syndrome have been reported in postmarketing experience with Rapivab. Discontinue Rapivab and institute appropriate treatment if anaphylaxis or a serious skin reaction occurs or is suspected. The use of Rapivab is contraindicated in patients with known serious hypersensitivity or anaphylaxis to Rapivab.

  • Patients with influenza may be at an increased risk of hallucinations, delirium, and abnormal behavior early in their illness. There have been postmarketing reports (from Japan) of delirium and abnormal behavior leading to injury in patients with influenza who were receiving neuraminidase inhibitors, including Rapivab. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon. These events were reported primarily among pediatric patients. The contribution of Rapivab to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior.

  • Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Rapivab has not been shown to prevent such complications.

Adverse Reactions

The most common adverse reaction was diarrhea (8% Rapivab vs 7% placebo).

Lab abnormalities (incidence ≥2%) occurring more commonly with Rapivab than placebo were elevated ALT 2.5 times the upper limit of normal (3% vs 2%), elevated serum glucose >160 mg/dL (5% vs 3%), elevated CPK at least 6 times the upper limit of normal (4% vs 2%) and neutrophils <1.0 x 109/L (8% vs 6%).

Concurrent Use With Live Attenuated Influenza Vaccine

Antiviral drugs may inhibit viral replication of a live attenuated influenza vaccine (LAIV). The concurrent use of Rapivab with LAIV intranasal has not been evaluated. Because of the potential for interference between these two products, avoid use of Rapivab within 2 weeks after or 48 hours before administration of LAIV unless medically indicated.

Please see full prescribing information for Rapivab.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088.